Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F

Open source

DOI
10.1186/s12885-019-5498-3
Published
2019 Mar 29
Container
BMC cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12885-019-5498-3,
  title = {Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.},
  author = {Di Bartolomeo M and Niger M and Morano F and Corallo S and Antista M and Tamberi S and Lonardi S and Di Donato S and Berardi R and Scartozzi M and Cardellino GG and Di Costanzo F and Rimassa L and Luporini AG and Longarini R and Zaniboni A and Bertolini A and Tomasello G and Pinotti G and Scagliotti G and Tortora G and Bonetti A and Spallanzani A and Frassineti GL and Tassinari D and Giuliani F and Cinieri S and Maiello E and Verusio C and Bracarda S and Catalano V and Basso M and Ciuffreda L and De Vita F and Parra HS and Fornaro L and Caporale M and de Braud F and Pietrantonio F},
  year = {2019},
  journal = {BMC cancer},
  doi = {10.1186/s12885-019-5498-3},
  url = {https://doi.org/10.1186/s12885-019-5498-3}
}

RIS

TY  - JOUR
TI  - Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
AU  - Di Bartolomeo M
AU  - Niger M
AU  - Morano F
AU  - Corallo S
AU  - Antista M
AU  - Tamberi S
AU  - Lonardi S
AU  - Di Donato S
AU  - Berardi R
AU  - Scartozzi M
AU  - Cardellino GG
AU  - Di Costanzo F
AU  - Rimassa L
AU  - Luporini AG
AU  - Longarini R
AU  - Zaniboni A
AU  - Bertolini A
AU  - Tomasello G
AU  - Pinotti G
AU  - Scagliotti G
AU  - Tortora G
AU  - Bonetti A
AU  - Spallanzani A
AU  - Frassineti GL
AU  - Tassinari D
AU  - Giuliani F
AU  - Cinieri S
AU  - Maiello E
AU  - Verusio C
AU  - Bracarda S
AU  - Catalano V
AU  - Basso M
AU  - Ciuffreda L
AU  - De Vita F
AU  - Parra HS
AU  - Fornaro L
AU  - Caporale M
AU  - de Braud F
AU  - Pietrantonio F
PY  - 2019
JO  - BMC cancer
DO  - 10.1186/s12885-019-5498-3
UR  - https://doi.org/10.1186/s12885-019-5498-3
ER  -

APA

M, D. B., M, N., F, M., S, C., M, A., S, T., S, L., S, D. D., R, B., M, S., GG, C., F, D. C., L, R., AG, L., R, L., A, Z., A, B., G, T., G, P., G, S., G, T., A, B., A, S., GL, F., D, T., F, G., S, C., E, M., C, V., S, B., V, C., M, B., L, C., F, D. V., HS, P., L, F., M, C., F, D. B., & F, P. (2019). Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.. BMC cancer. https://doi.org/10.1186/s12885-019-5498-3

Source records